NF-κΒ activator 1 is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD) 2 mRNA expression.

BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM.

ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor. ThioLox shows anti-inflammatory and neuroprotective properties.

CAY10462 is the hydrochloride salt of CAY10434 and selective inhibitor of the 20-HETE synthase CYP4A11 exhibiting an IC50 of 8.8 nM when tested in human renal microsomes.4 CAY10434 is nearly 200 times less potent as an inhibitor of 1A, 1C, and 3A CYP450.

Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM).

J 3-54 , also known as LSD1-IN-24, is a selective LSD1 inhibitor with IC50 = 0.247 μM. VUN34592 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research.

DKI5, also known as (E)-N’-benzylidenehydrazinecarbothiohydrazide, is a LOX-1 inhibitor with an IC50 value of 22.5 μM. DKI5 strongly inhibits lipid peroxidation.

HUN39963, also known as LDH-IN-2 is an inhibitor of glycolate oxidase. This compound was first reported in J Med Chem.

VUN28691, also known as p38α inhibitor 3, is a p38α inhibitor for treatment of p38-α kinase-mediated conditions.

GSK3β Inhibitor II, also known as KIN 001-042, also known as GSK-3β Inhibitor II, is a GSK-3β inhibitor.

CUN11141, also known as BRD4 Inhibitor-20, is a potent orally active bromodomain protein 4 (BRD4) inhibitor. It can be used for the research of kinds of cancer, such as colon cancer.

ZVN26391, also known as NLRP3-IN-10, is a IL-1β inhibitor for the treatment of inflammation and inflammation-related disease (neurogenic inflammation, Alzheimer disease, etc.).

WAY-299838 is a useful chemical agent for chemical synthesis of hypoxia-inducible factor-1 inhibitor.

RXN00442, also known as EGFR-IN-11, is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). This compound was first reported in Eur J Med Chem.

WAY-658513 is a multiple kinase inhbitor. WAY658513 was shown to inhibit ROCK I, ERK2, GSK3, and PKA with Ki <1 μM.

NSC321039, also known as hMAO-B-IN-4, is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value of 0.067 μM.

BDTX-1535 is a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).

Moracin C is a phenolic compound isolated from Artocarpus heterophyllus. Moracin C suppresses Lipopolysaccharide-Activated Inflammatory Responses in Murine Raw264.7 Macrophages.

CPPHA is a selective positive allosteric modulator of mGluR5 receptor.

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.

DCFH, also known as 2',7'-dichlorodihydrofluorescein, is a fluororescent agent. It is a key chemcial for the dichlorofluorescin (DCFH) oxidation assay.

AD-57, also known as KIRA 1, is an IRE1 inhibitor for cancer inflammation autoimmune disease therapy.

WAY-640810 is a chemical agent which may alter the lifespan of a eukaryotic organism.

WAY-313013 is a p38a Mitogen-Activated Protein Kinase inhibitor.

LUN09945 is a potent RETV804M kinase inhibitor. LUN09945 was first reported by Rebecca Newton et al (Compound 13, in ACS Med Chem Lett. 2020;11(4):497-505). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature

Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.

(R)-V-0219 is an enantiomer of V-0219. V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R.

RAY1216 is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.

N-hydroxymethyl succinimide is used as pharmaceutical intermediate.